Entrada Therapeutics announced the closing of a Strategic Collaboration and License Agreement with Vertex Pharmaceuticals, including the sale of 1,618,613 shares of common stock to Vertex for $26.3 million.
AI Assistant
ENTRADA THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.